Epithelial cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Ovarian cancer epithelial is the most common type. This cancer develops in the ovary's epithelial tissue, a thin layer that covers the exterior of the organ. Cancer can also form in a fallopian tube's lining. As an alternative, the peritoneum, the tissue that envelops the abdominal organs, may be the place where it begins. More than 95% of ovarian malignancies are caused by epithelial ovarian cancer (EOC), which is the most common type. Acute or subacute clinical manifestations of EOC are possible. Due to aging populations in high-income countries as well as rising rates in many low- and middle-income countries, ovarian cancer continues to be a leading cause of morbidity and mortality worldwide. Surgery is frequently the first course of treatment for ovarian cancer if the patient is in good health. Neoadjuvant chemotherapy, which is followed by interval debulking surgery and additional chemotherapy, should be considered for patients who are not good candidates for optimal debulking.

Description

The epithelial subtype of ovarian cancer is the most common as this cancer develops in the thin layer of tissue called epithelial tissue that covers the outside of an ovary. Cancer can also form in a fallopian tube's lining. Alternatively, the tissue that envelops the abdominal organs, the peritoneum, could be the place where it begins. Among the conditions that acute cases present with are small bowel obstruction, venous thromboembolism, and pleural effusion. Subacute cases may present with nonspecific symptoms such as an adnexal mass, nebulous pelvic or abdominal pain, and gastrointestinal symptoms. Various types of epithelial ovarian cancer exist, including those that are serous, endometrioid, clear cell, mucinous, undifferentiated, or unclassifiable. Epithelial ovarian cancer, which typically manifests at an advanced stage, is responsible for the majority of gynecological cancer-related fatalities.

Epithelial cancer (Epidemiology)

Over 95% of ovarian malignancies are caused by epithelial ovarian cancer (EOC), which is the most common type. Acute or subacute clinical manifestations of EOC are possible. Ovarian cancer continues to be a leading cause of morbidity and mortality worldwide, with rising rates in many low- and middle-income countries and rising case numbers in high-income countries as a result of population aging. The proportion of women who pass away from their disease has not changed significantly over time when compared to other common cancer types, and the five-year relative survival rate is under 45%. Epithelial ovarian cancer is known to be associated with a number of risk and protective factors, the majority of which are hormonal and reproductive in nature. Tubal ligation, higher parity, and the use of oral contraceptives all significantly reduced risk, whereas a history of endometriosis, smoking, older menopausal age, obesity, and menopausal hormone therapy significantly increased risk. With 240,000 women receiving a diagnosis each year, ovarian cancer is the eighth most common cancer among women in the world and the seventh most common cause of cancer death. It also results in 150,00 deaths and has a five-year survival rate below 45%. Because rates have been falling in many high incidence countries while rising in many low incidence countries, the differences are less pronounced today than they were thirty years ago. As an example, in the United States, non-Hispanic white women's rates are roughly 30% higher than those of African American and Asian women, and 16% higher than those of Hispanic women. Within nations, rates also vary by ethnicity. Ovarian cancer is rare in women under 40, and germ cell tumors are more common in this age group. The risk increases with age, peaking in the late 70s, and over 90% of tumors in people over the age of 40 are epithelial tumors.

Epithelial cancer -Current Market Size & Forecast Trends

The market for epithelial cancer, specifically focusing on differentiated types such as epithelial ovarian cancer, is projected to experience significant growth. The epithelial ovarian cancer treatment market was valued at approximately USD 3.5 billion in 2023 and is expected to reach around USD 6.1 billion by 2030, reflecting a compound annual growth rate (CAGR) of about 9.4% during this period. This growth is driven by increasing incidences of epithelial cancers, advancements in treatment options including targeted therapies and immunotherapies, and rising awareness and early detection initiatives. The overall oncology market, which includes various epithelial cancers, is also expected to expand significantly, with estimates suggesting it could reach USD 335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033. North America is anticipated to dominate the market due to its advanced healthcare infrastructure and substantial investments in cancer research, while the Asia-Pacific region is projected to witness rapid growth as healthcare access improves. Overall, the epithelial cancer market is well-positioned for robust expansion through 2035 as new therapies continue to emerge and patient awareness increases.

Surgery, chemotherapy, and radiation therapy-the last of which is only rarely used-are the three main forms of treatment for ovarian cancer. Surgery is the main method of treatment for ovarian cancer. The histologic subtype and stage at diagnosis are the primary determining factors of treatment. These factors are assessed surgically through a tumor-reductive procedure that may involve hysterectomy, removal of the ovaries, removal of the omentum, and removal of any other disease sites that are amenable to removal. Although a patient is considered to be in "optimal" status if there are no residual lesions larger than 1 cm, the goal of surgery is to reduce the tumor burden until there is no discernible disease. Surgery is frequently the first line of ovarian cancer treatment if the patient is in good health. Neoadjuvant chemotherapy, which is followed by interval debulking surgery and additional chemotherapy, should be considered for patients who are not good candidates for optimal debulking. Chemotherapy may be used as a first treatment option when a patient is not healthy enough for surgery before surgery is even considered. Removing all visible tumors, establishing the diagnosis, and figuring out the severity of the condition are the objectives of surgery. Utilizing a taxane and a platinum compound, chemotherapy should be combined with surgery (e.g., paclitaxel and carboplatin combined). Patients with BCRA mutations may have a significantly longer survival after surgery and/or chemotherapy when receiving maintenance therapy with olaparib, with or without bevacizumab. When a female patient presents with peritoneal carcinomatosis but no obvious pelvic mass, a thorough search frequently results in nothing. Platinum-based chemotherapy and cytoreductive surgery are effective treatments for these patients who are likely suffering from primary ovarian or peritoneal cancer. Adjuvant chemotherapy with carboplatin and paclitaxel is suggested for all high-grade ovarian and tubal cancers (FIGO stages I-IIA).

Report Highlights

Epithelial cancer - Current Market Trends

Epithelial cancer - Current & Forecasted Cases across the G8 Countries

Epithelial cancer - Market Opportunities and Sales Potential for Agents

Epithelial cancer - Patient-based Market Forecast to 2035

Epithelial cancer - Untapped Business Opportunities

Epithelial cancer - Product Positioning Vis-a-vis Competitors' Products

Epithelial cancer - KOLs Insight